TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06467474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEG-D program
Description: PEG-D will be carried out in person, open format, for six consecutive weeks lasting 90 minutes each. An approximate group of 6 to 10 participants will be led by a team of experienced psychologists and psychiatrists. Each group will have a main therapist and a co-therapist to ensure effective support and guidance for participants. Before the start of the group, participants received a booklet containing the content of the sessions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAU
Description: The treatment will start with Sertraline (SSRI) - doses of 50 mg and adjusting as necessary according to the patient\&#39;s profile. After 8 weeks, if the patient experiences remission, they will continue on monotherapy with Sertraline. In case of relapse Bupropion, Quetiapine, Lithium or Aripiprazole might be add-on. In this case, add-on medications will be determined according to the patient profile, by the clinician. If there is a response above 25% of the symptoms, but without remission, the patient will proceed to augmentation with the aforementioned medications and if there is no improvement of at least 25%, the patient will be considered drop-out. Associations with Lorazepam if necessary will be allowed in any phase of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: The treatment will start with Sertraline (SSRI) - doses of 50 mg and adjusting as necessary according to the patient\&#39;s profile. After 8 weeks, if the patient experiences remission, they will continue on monotherapy with Sertraline. In case of relapse Bupropion, Quetiapine, Lithium or Aripiprazole might be add-on. In this case, add-on medications will be determined according to the patient profile, by the clinician. If there is a response above 25% of the symptoms, but without remission, the patient will proceed to augmentation with the aforementioned medications and if there is no improvement of at least 25%, the patient will be considered drop-out. Associations with Lorazepam if necessary will be allowed in any phase of the study.
Study: NCT05512572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPL
Description: intense pulsed light

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment or excision with curettage
Description: conservative treatment or excision with curettage but without IPL-MGX treatment as a control
Study: NCT05262608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Lynparza (Olaparib tablets) 300 mg should be taken orally twice daily
Study: NCT06455384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genetics Navigator
Description: The Genetics Navigator will be used to support patients during the delivery of genetic services, including intake, education, pre- and post-test counselling, and physician-generated management recommendations
Study: NCT04736030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Twelve weekly sessions will be led by Ms. Schneider and Ms. Montañez supported by Drs. Arredondo and Ayala and student research assistants. Mothers and daughters will participate in weekly virtual 1.5-hour sessions that include didactic teaching, skill building (including PA parenting and communication skills training), interactive discussions, PA, and homework review (homework examples: 30-min walks, practicing communication strategies). Mothers and daughters will attend sessions together, with 10-12 mother-daughter dyads participating in each series. Sessions 2-12 will include at least 30 min PA. Sessions will discuss strategies to engage in PA outside the sessions (goal of 60-min MVPA daily).
Study: NCT06455384

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care with Genetics Professionals
Description: Standard care for the delivery of genetic services, including receiving genetic counselling and test results
Study: NCT06504641

Intervention type: OTHER
Intervention: Isla for Frailty
Description: Isla for Frailty - video-based patient records. Isla is a technology company providing a visual patient record platform. The platform allows anyone involved in a patient's care to capture and review visual data (photographs, videos) relating to a patient's health. The platform is web-based (a progressive web application) and supports secure capture of visual data with encrypted storage in the cloud.~Isla interfaces with Electronic Health Record (EHR) systems including Cerner, enabling health professionals to view data held on Isla's servers from within the electronic patient record, via the 'Cerner Red Button'. Health professionals can also view a patient's visual record through a secure weblink requiring an NHS email address and password.

Intervention type: OTHER
Intervention: Isla for Frailty
Description: Isla for Frailty - video-based patient records. Isla is a technology company providing a visual patient record platform. The platform allows anyone involved in a patient's care to capture and review visual data (photographs, videos) relating to a patient's health. The platform is web-based (a progressive web application) and supports secure capture of visual data with encrypted storage in the cloud.~Isla interfaces with Electronic Health Record (EHR) systems including Cerner, enabling health professionals to view data held on Isla's servers from within the electronic patient record, via the 'Cerner Red Button'. Health professionals can also view a patient's visual record through a secure weblink requiring an NHS email address and password.

Intervention type: OTHER
Intervention: Isla for Frailty
Description: Isla for Frailty - video-based patient records. Isla is a technology company providing a visual patient record platform. The platform allows anyone involved in a patient's care to capture and review visual data (photographs, videos) relating to a patient's health. The platform is web-based (a progressive web application) and supports secure capture of visual data with encrypted storage in the cloud.~Isla interfaces with Electronic Health Record (EHR) systems including Cerner, enabling health professionals to view data held on Isla's servers from within the electronic patient record, via the 'Cerner Red Button'. Health professionals can also view a patient's visual record through a secure weblink requiring an NHS email address and password.
Study: NCT06037447

Intervention type: PROCEDURE
Intervention: 3-steps standardized repair-oriented strategy
Description: 3-steps standardized repair-oriented strategy, including subvalvular apparatus rehabilitation (leaflet plication if chordae absent on leaflet margin, mal-connected chordae resection if chordae mal-connected to leaflet body, papillary muscle splitting if short chordae or dysplastic or fused papillary muscle etc.), leaflets repair (leaflets plication if functional leaflet prolapse, leaflet cleft closure and patch augmentation for anatomical leaflet defect, etc.) and annuloplasty (posterior annuloplasty for annular dilatation and shallow leaflet coaptation, etc.)
Study: NCT05820178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: On the basis of conventional treatment, tDCS was given on day 2 after enrollment for a total of 14 days, once a day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: On the basis of conventional treatment, rTMS was given on day 2 after enrollment for a total of 14 days, once a day.
Study: NCT04892680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Diabetes Self-Management Education and Support (DSMES) Program
Description: Digital delivery of a DSMES program designed to build self-management skills and support diabetes management. Recipients have access to online curriculum, a live CDCES, group-based communication forums, and connected technology to track weight, food intake, physical activity and glucose levels.
Study: NCT04841850

Intervention type: OTHER
Intervention: Clinical and biological characteristics
Description: * Age at beginning of IOT~* Sex~* Atopic and non atopic Comorbidities~* Sensitization to aero-allergens~* Sensitization to trophallergens~* Stage of severity of the elicited reaction~* Hazelnut Specific IgE + Cor a 1,8,9,14 before IOT and during follow up~* Hazelnut skin prick test before IOT and during follow up~* Adverse effects of IOT and their stage (in hospital and at home)~* Use of adrenaline auto-injector (in hospital and at home)~* Maintenance dose
Study: NCT06244719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile Stimulation
Description: Shirts contain embedded vibration motors that stimulate the impaired upper-extremity at 18 different locations. The gloves stimulates the fingertips.
Study: NCT05157776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1 and chemotherapy
Description: Sintilimab+(Squamous)ABX+DDP/CBP, or (non-Squamous)PEM+DDP/CBP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 and chemotherapy
Description: Sintilimab+(Squamous)ABX+DDP/CBP, or (non-Squamous)PEM+DDP/CBP
Study: NCT05405972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Connected Family Series - For Foster Families
Description: A 4-week program involving videos and activities for both the parent and child in the home.
Study: NCT06389643

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four-point scleral fixation of Akreos AO60 IOL
Description: Intrascleral tunnels were marked at a distance of 2 mm from the corneal limbus, 6 mm apart (4 in number) after retrobulbar anesthesia. Next corneal incisions were performed. An artificial lens was then implanted into the anterior chamber. The 6-0 polypropylene suture was introduced into the anterior chamber through openings in the cornea. The next stage was to perform a sclerotomy using a 30G needle. Then the needle was passed through the hole in the haptic and 6-0 polypropylene suture was inserted into the needle hole and guided outside. The other end of the suture, passed through the opening in the haptic, was placed in the lumen of the needle and carried out through another sclerotomy and then externalised. This maneuver was repeated with another haptics as well. Correct position of the IOL in the eye was achieved by pulling on the ends of the monofilament. The ends of sutures were trimmed and cauterized. The melted tips of the sutures were then fixed subconjunctivally.
Study: NCT05193929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OptiPulse™
Description: TheOptiPulse™ is designed to enhance blood circulation in the venules and arterioles in subjects with diabetic foot ulcers of the lower extremities. OptiPulse™ is supplied as a pair of footwear. One side is fitted with an off loader and shin pumping unit, and the other acts as pressure reducing footwear.Both active and non-active footwear should be worn to give balanced gait

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care offloading device
Description: CAM boot
Study: NCT06389643

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sutureless scleral fixation of AcrySof MA60AC IOL with Yamane technique
Description: The surgery was performed under retrobulbar anesthesia. The first step of the procedure was to mark the locations of the intrascleral tunnels (2 mm from the corneal limbus) and locate them at a distance of 180° from each other to prevent the lens from tilting in the eyeball. Openings in the cornea were done. Three-piece IOL was implanted into the anterior chamber. The first sclerotomy was performed through the conjunctiva using a 30G needle 2 mm from the limbus. One of the haptics was inserted into the needle lumen and then brought out. Same procedure was performed with another haptic at a distance of 180°. The next step was to perform cautery of the tips of the haptics, obtaining a 0.3 mm collar that prevents the risk of the haptic coming out of the tunnel and displacing the lens inside the eyeball. The tips of the haptics were finally gently inserted into the scleral canals and covered with conjunctiva.
Study: NCT05351606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Given orally
Study: NCT05004870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound performed by a woman herself (with HCP supervision via telemedicine)
Description: The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
Study: NCT05325671

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transarticular multimodal drug infiltration
Description: as described previously

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarticular multimodal drug infiltration
Description: as described previously
Study: NCT05021497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Positional Re-education
Description: A series of gentle active movements and postures aimed at realigning joints and stretching shortened muscles. GPR includes 8 therapeutic postures in lying, sitting and standing.
Study: NCT05351606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Given transdermally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Given transdermally
Study: NCT05021497

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy Program
Description: Axial traction will be given for 5 minutes, followed by mobilization of the muscle fascia along with static stretching of the scalene, levator scapulae, upper trapezius, sternocleidomastoid and pectoralis minor muscles.
Study: NCT04742985

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea combined extracts group
Description: Green tea combined extracts 320 mg/day (main compound 62,5 mg for A group, 125 mg for B group) during 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea combined extracts group
Description: Green tea combined extracts 320 mg/day (main compound 62,5 mg for A group, 125 mg for B group) during 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo 320 mg/day during 8 weeks
Study: NCT05590130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Oxygen titration with Philips oximeter (SpO2 target 90%)
Description: Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 90%) with Philips oximeter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual oxygen titration with Nonin oximeter (SpO2 target 90%)
Description: Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 90%) with Nonin oximeter
Study: NCT05351606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: Given orally
Study: NCT04871139

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Mammography
Description: Undergo CEM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radioactive Iodine
Description: Given IV
Study: NCT06046729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrekibart
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrekibart
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrekibart
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT05793112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INF108F probiotic
Description: Oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension
Study: NCT06445569

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: KH-1
Description: 3 capsules and one stick packet consumed daily around the same time

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules and one stick packet consumed daily around the same time
Study: NCT04896749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nerve mobilization
Description: Moist pack all over cervical spine for 10 minutes. TENS for 10 minutes at frequency of 60 Hz with 2 electrodes. Cervical traction for 10 minutes with 7 sec hold and 5 sec rest time. Cervical isometric exercises with 7 sec hold and 30 repetitions in each direction twice a day.~Median, ulnar and radial nerve stretch with 3 sets of 10 repetitions , with 3 sec hold at final stretched position.~Following nerve mobilizations are used in experimental group/group A:~Median Nerve: Glenohumeral abduction, wrist extension, supination, glenohumeral lateral rotation, elbow extension, neck lateral bending to opposite side. Radial Nerve: Glenohumeral depression, elbow extension, whole arm internal rotation, wrist flexion Ulnar Nerve: Wrist extension, forearm pronation elbow flexion, glenohumeral lateral rotation, glenohumeral depression, shoulder abduction each with 3 sets of 10 repetitions , with 3 sec hold at final stretched position.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Moist pack for 10 minutes. TENS for 10 minutes at frequency of 60 Hz with 2 electrodes. Cervical traction for 10 minutes with 7 sec hold and 5 sec rest time. Cervical isometric exercises with 7 sec hold and 30 repetitions in each direction twice a day.
Study: NCT05473962

Intervention type: DIAGNOSTIC_TEST
Intervention: assessment and quantification of symptoms related to post-traumatic stress.
Description: Semi-structured interview based on the Clinician-Administered PTSD scale for DSM-5 Child/Adolescent -CAPS-CA-5. This instrument allows for the This instrument is validated in English, and a French translation was carried out by the investigators (translation/back-translation method). The instrument uses the DSM-5 diagnostic criteria for post-traumatic stress disorder (PTSD).
Study: NCT05979649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral corrective tasks
Description: After each personalized conversation, the interveners will, based on a clear understanding of the participants' completion status and personal experiences with the previous behavioral corrective tasks, assist in formulating future behavioral corrective tasks for the next two weeks. These tasks will be selected from our designated To Do List, requiring at least one task from each category: social support, coping strategies, and emotional intelligence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counselling on psychological knowledge
Description: Counselling on psychological knowledge includes weekly personalized feeds, as well as the methods and techniques for coping with challenges provided by the interveners.during personalized conversations with the participants.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo-controlled study
Description: feel-good articles without professional psychological knowledge will be sent to the control group participants weekly.

Intervention type: OTHER
Group type: OTHER
Intervention: Peer Interventionist Training
Description: The training is a one-day course, encompassing a broad range of topics, including but not limited to counseling techniques and specialized medical psychology knowledge.
Study: NCT04376762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Description: Fibrinogen Concentrate (Human) Injection \[Fibryga\] (dose: 70 mg/kg; intervention group). in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF \< 10 mm on the FIBTEM assay of ROTEM).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprecipitate
Description: Cryoprecipitate group (dose: 10 ml/kg; active control group) in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF \< 10 mm on the FIBTEM assay of ROTEM).
Study: NCT04602715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MET-2
Description: Subjects will take capsules containing MET-2 daily during the trial. There will be a loading dose at the start of dosing, and a daily dose. There will be a booster dose given at week 2 and a second booster dose taken at week 4 for those subjects who have not improved by that time.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Control
Study: NCT05870137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HoloLens2TM
Description: Participants assigned to Mixed Reality-supported care used the HoloLens2 device, which provided support using technology that was permitted by the device. This support included remote assistance and holographic versions of patient-specific investigation results, such as radiological findings, biochemistry, and guidelines for completing the procedure (insertion of chest drain).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The standard care for the intervention involved participants performing the invasive technical procedure to treat a tension pneumothorax using their standard clinical skills and knowledge, without the aid of the HoloLens2 device. The participants in the standard care group did not receive any additional support or guidance beyond what is typically available in a clinical setting. The goal of the study was to compare the effectiveness of the standard care approach with the use of Mixed Reality-supported care using the HoloLens2 device.
Study: NCT05736627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online
Description: Online research course delivered live digitally at a distance.
Study: NCT05590130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Oxygen titration with Philips oximeter (SpO2 target 94%)
Description: Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 94%) with Philips oximeter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual oxygen titration with Nonin oximeter (SpO2 target 94%)
Description: Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 94%) with Philips oximeter
Study: NCT05251571

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Exercise Group with Telerehabilitation
Description: Exercises such as conventional muscle strengthening and stretching given with telerehabilitation are applied.
Study: NCT05484037

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CANATEXTS
Description: Canadian Asthma Text Messaging (CANATEXTS) is a TH intervention facilitating access to an electronic AAP (eAAP) via a mobile device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CANATEXTS
Description: Canadian Asthma Text Messaging (CANATEXTS) is a TH intervention facilitating access to an electronic AAP (eAAP) via a mobile device.